GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Shiller PE Ratio

GT Biopharma (GT Biopharma) Shiller PE Ratio : (As of Jun. 23, 2024)


View and export this data going back to . Start your Free Trial

What is GT Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GT Biopharma Shiller PE Ratio Historical Data

The historical data trend for GT Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma Shiller PE Ratio Chart

GT Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GT Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GT Biopharma's Shiller PE Ratio

For the Biotechnology subindustry, GT Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Shiller PE Ratio falls into.



GT Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GT Biopharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, GT Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.64/131.7762*131.7762
=-1.640

Current CPI (Mar. 2024) = 131.7762.

GT Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -18,714.300 100.560 -24,523.783
201409 -281,333.000 100.428 -369,150.710
201412 -1,242,400.000 99.070 -1,652,561.286
201503 -1,367,730.000 99.621 -1,809,197.670
201506 1,790,670.000 100.684 2,343,648.667
201509 -112,800.000 100.392 -148,063.883
201512 -1,738,870.000 99.792 -2,296,183.686
201603 104,142.000 100.470 136,591.842
201606 9,130.180 101.688 11,831.674
201609 -19,728.300 101.861 -25,522.235
201612 -13,867.600 101.863 -17,940.027
201703 -6,298.880 102.862 -8,069.461
201706 -2,531.350 103.349 -3,227.621
201709 -4,156.470 104.136 -5,259.717
201712 -61.320 104.011 -77.689
201803 -101.999 105.290 -127.658
201806 -91.799 106.317 -113.782
201809 -2,396.980 106.507 -2,965.681
201812 -35.700 105.998 -44.382
201903 -45.900 107.251 -56.396
201906 -25.500 108.070 -31.094
201909 -260.098 108.329 -316.394
201912 9.416 108.420 11.444
202003 -12.300 108.902 -14.884
202006 -123.600 108.767 -149.747
202009 -19.200 109.815 -23.040
202012 -39.600 109.897 -47.484
202103 -54.900 111.754 -64.736
202106 -4.500 114.631 -5.173
202109 -5.100 115.734 -5.807
202112 -15.600 117.630 -17.476
202203 -5.100 121.301 -5.540
202206 -3.000 125.017 -3.162
202209 -6.600 125.227 -6.945
202212 -5.063 125.222 -5.328
202303 -0.210 127.348 -0.217
202306 -1.500 128.729 -1.536
202309 -1.800 129.860 -1.827
202312 -1.984 129.419 -2.020
202403 -1.640 131.776 -1.640

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GT Biopharma  (NAS:GTBP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


GT Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GT Biopharma (GT Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Executives
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen director, officer: Exec. Chair. and Interim CEO LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri officer: CFO & Secretary 2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel director 70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk officer: Pres. of R&D, CMO HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban director 1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy officer: Acting Chief Financial Officer 8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon director, officer: CFO 7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross director, officer: Chief Executive Officer 1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski officer: Chief Medical Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith director, 10 percent owner, officer: CEO 1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman 10 percent owner 224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc 10 percent owner
Bristol Investment Fund Ltd 10 percent owner 89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205

GT Biopharma (GT Biopharma) Headlines